214 related articles for article (PubMed ID: 35582727)
1. Pharmacogenetics of thiopurines.
Franca R; Zudeh G; Pagarin S; Rabusin M; Lucafò M; Stocco G; Decorti G
Cancer Drug Resist; 2019; 2(2):256-270. PubMed ID: 35582727
[TBL] [Abstract][Full Text] [Related]
2. Optimizing thiopurine therapy in children with acute lymphoblastic leukemia: A promising "MINT" sequencing strategy and therapeutic "DNA-TG" monitoring.
Guo HL; Zhao YT; Wang WJ; Dong N; Hu YH; Zhang YY; Chen F; Zhou L; Li T
Front Pharmacol; 2022; 13():941182. PubMed ID: 36238550
[TBL] [Abstract][Full Text] [Related]
3. Multilocus genotypes of relevance for drug metabolizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia.
Stocco G; Franca R; Verzegnassi F; Londero M; Rabusin M; Decorti G
Front Genet; 2012; 3():309. PubMed ID: 23335936
[TBL] [Abstract][Full Text] [Related]
4. Landscape of TPMT and NUDT15 Pharmacogenetic Variation in a Cohort of Canadian Pediatric Inflammatory Bowel Disease Patients.
Kennedy AM; Griffiths AM; Muise AM; Walters TD; Ricciuto A; Huynh HQ; Wine E; Jacobson K; Lawrence S; Carman N; Mack DR; deBruyn JC; Otley AR; Deslandres C; El-Matary W; Zachos M; Benchimol EI; Critch J; Schneider R; Crowley E; Li M; Warner N; McGovern DPB; Li D; Haritunians T; Rudin S; Cohn I
Inflamm Bowel Dis; 2024 May; ():. PubMed ID: 38788739
[TBL] [Abstract][Full Text] [Related]
5.
Moradveisi B; Muwakkit S; Zamani F; Ghaderi E; Mohammadi E; Zgheib NK
Front Pharmacol; 2019; 10():916. PubMed ID: 31507415
[No Abstract] [Full Text] [Related]
6. The Role of TPMT, ITPA, and NUDT15 Variants during Mercaptopurine Treatment of Swedish Pediatric Patients with Acute Lymphoblastic Leukemia.
Wahlund M; Nilsson A; Kahlin AZ; Broliden K; Myrberg IH; Appell ML; Berggren A
J Pediatr; 2020 Jan; 216():150-157.e1. PubMed ID: 31635813
[TBL] [Abstract][Full Text] [Related]
7. Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia.
Dorababu P; Nagesh N; Linga VG; Gundeti S; Kutala VK; Reddanna P; Digumarti R
Eur J Clin Pharmacol; 2012 Apr; 68(4):379-87. PubMed ID: 22009189
[TBL] [Abstract][Full Text] [Related]
8. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers for gastrointestinal adverse events related to thiopurine therapy.
Zudeh G; Franca R; Stocco G; Decorti G
World J Gastroenterol; 2021 Oct; 27(38):6348-6356. PubMed ID: 34720526
[TBL] [Abstract][Full Text] [Related]
10. Thiopurine S-methyltransferase pharmacogenetics in childhood acute lymphoblastic leukemia.
Yang JJ; Bhojwani D
Methods Mol Biol; 2013; 999():273-84. PubMed ID: 23666706
[TBL] [Abstract][Full Text] [Related]
11. Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response.
Abaji R; Krajinovic M
Pharmgenomics Pers Med; 2017; 10():143-156. PubMed ID: 28507448
[TBL] [Abstract][Full Text] [Related]
12. Genotyping NUDT15*3 rs1166855232 reveals higher frequency of potential adverse effects of thiopurines in Natives and Mestizos from Mexico.
Texis T; Guzmán-Cruz C; Rodríguez-Dorantes M; Sánchez-García S; Mino-León D; Gonzalez-Covarrubias V
Pharmacol Rep; 2022 Feb; 74(1):257-262. PubMed ID: 34091879
[TBL] [Abstract][Full Text] [Related]
13. The Effect of
Lee JM; Shim YJ; Kim DH; Jung N; Ha JS
Children (Basel); 2021 Mar; 8(3):. PubMed ID: 33804051
[TBL] [Abstract][Full Text] [Related]
14. Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry.
Schaeffeler E; Jaeger SU; Klumpp V; Yang JJ; Igel S; Hinze L; Stanulla M; Schwab M
Genet Med; 2019 Sep; 21(9):2145-2150. PubMed ID: 30728528
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.
Stocco G; Crews KR; Evans WE
Expert Opin Drug Saf; 2010 Jan; 9(1):23-37. PubMed ID: 20021291
[TBL] [Abstract][Full Text] [Related]
16. [The usefulness of pharmacogenetics for a more individualized treatment. The example thiopurines in inflammatory bowel disease and childhood leukemia].
Lindqvist Appell M; Mårtensson LG; Almer S; Peterson C
Lakartidningen; 2015 Jun; 112():. PubMed ID: 26126006
[TBL] [Abstract][Full Text] [Related]
17. Role of TPMT and ITPA variants in mercaptopurine disposition.
Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K
Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of thiopurines in inflammatory bowel disease.
Derijks LJ; Wong DR
Curr Pharm Des; 2010; 16(2):145-54. PubMed ID: 20205660
[TBL] [Abstract][Full Text] [Related]
19. Effects of
Mao X; Yin R; Sun G; Zhou Y; Yang C; Fang C; Wu Y; Cui T; Liu L; Gan J; Tian X
Front Pediatr; 2021; 9():719803. PubMed ID: 34660484
[No Abstract] [Full Text] [Related]
20. Meta-analysis: Inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease.
Van Dieren JM; Hansen BE; Kuipers EJ; Nieuwenhuis EE; Van der Woude CJ
Aliment Pharmacol Ther; 2007 Sep; 26(5):643-52. PubMed ID: 17697198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
